FAVO brings together more than 500 #cancer patients organizations in #Italy, ensuring their voice is represented with health stakeholders and with institutions
💪💥Proud that the voice of #cancer patients is represented in such an high-level congress! Our President #DeLorenzo kicked-off the session on Precision Oncology and #biomarkers, key topics of both the EU Cancer Plan and Cancer Mission! 🎯🇪🇺
@uicc @cancereu #worldcancercongress
ECPC @cancereu session at @UICC congress 2day: #PrecisionOncology & #Biomarkers: Opening new Therapeutic Avenues for cancer patients
F de Lorenzo presented ECPC involvement in #personalized med & biomarkers
N Normanno: PRECISION ONCOLOGY AND BIOMARKERS: A BRIDGE TO THE FUTURE
The European Cancer Patient Coalition - ECPC @cancereu welcomes its new Board of Directors and its new Audit Committee for the mandate June 2022-May 2025
We wish them all a good start & look forward to welcome them in Brussels at the ECPC AGM on May 28
https://t.co/7x9PnJwUzb
Are you a patient diagnosed with a #desmoid tumor BEFORE or DURING #pregnancy? If your answer is YES, please take part of this study.
You will find the form to fill out on our website: https://t.co/Kny7llJIkU
Support #research!
#df#desmoidfoundation#RareDisease
President of @favo_it Francesco de Lorenzo presents JARC recommendations that were launched last year: https://t.co/Mxb99HwDbr
"Without application of the cross-border healthcare directive, there is no hope #rarecancers" #RareCancerDay
Prof Francesco De Lorenzo, past President ECPC @cancereu, talking on #rarecancers, stressed the importance of #ERNs & urged the Council to proceed to the implementation of the cross border health care
#ChallengeCancerIntergroup@FAVO_en
🎯FAVO was a pioneer in #Italy in highlighting the importance of cross border health care in #cancer care. This needs to be at the top of #EU agenda, especially for diseases that require an high level and very specialized care, such as #RareCancer.
#RareDiseaseDay@ChallengeCAN
Prof Francesco De Lorenzo, past President ECPC @cancereu, talking on #rarecancers, stressed the importance of #ERNs & urged the Council to proceed to the implementation of the cross border health care
#ChallengeCancerIntergroup@FAVO_en
An agenda on rare cancers was perceived as instrumental to prioritise rare cancers in the agenda of the EU 🧐 #RareDiseaseDay
What are the next steps? Do not miss this interesting discussion on the implementation of the Rare Cancer Agenda 2030 👉🏻 https://t.co/m4rXoIdsyU
💥Today our president De Lorenzo will attend the webinar 💻"EU Joint Action on Rare Cancers recommendations towards implementing the Rare Cancer Agenda 2030”. 💪Very excited to be there! #RareDiseaseDay#RareCancer
To join the discussion see below ⏬
Tomorrow MEPs, experts & patient advocates will discuss the roadmap to be followed in the implementation of the Rare Cancer Agenda 2030.
Have you not registered yet? Join us! https://t.co/zjWutrPbrV #RareDiseaseDay
Don’t miss the #ESMO Public Policy Webinar ‘Europe’s Beating Cancer Plan – in 60 Minutes’
on 15 February 15:30-16:30. More info 👉 https://t.co/hkptYyiV19. Registration 👉https://t.co/ZPLRtXFEvY @cancernurseEU@EU_Health@EFPIA @cancereu
🗓️On monday 15 feb our president will attend as a speaker at the @myESMO webinar "Europe’s Beating Cancer Plan - in 60 minutes". Proud to get involved in such an high level debate on the new EU strategy to beat #cancer 🇪🇺🎯!
Info & registration ➡️https://t.co/2FCCWDAQsB
Εlisabetta Iannelli @EIannelli, Lawyer,cancer survivor,Vice President AIMAC @aimac-Secretary FAVO @FAVO_en,both long standing members of ECPC @cancereu,was nominated by the Italian President Mattarella Commander of the Order of Merit" of the Italian Republic!
Congratulations!
⚠️In the fight against cancer being fast and effective is crucial. It is not acceptable that pricing and reimbursement mechanisms cause delays in access to innovative drugs, which can cost cancer patients' life years!
Now Prof. Francesco de Lorenzo will present now the patient perspective on Prof. Uul de Groot lecture "For the first time we have data for late access to new cancer medicines that may cost life years"